LY3540378 is a medication being tested in this clinical trial to see if it can help people with a type of heart failure called chronic heart failure with preserved ejection fraction (HFpEF). This condition means that the heart has trouble relaxing and filling with blood properly, even though it can still pump blood out to the body. The trial is looking at whether LY3540378 can improve a specific heart problem called atrial myopathy, which affects the upper chambers of the heart. The medication is given as an injection under the skin, and researchers are comparing it to a placebo to see if it works better in helping the heart function more effectively.

Heart Failure – Heart failure is a condition where the heart is unable to pump blood effectively to meet the body’s needs. It can result from various underlying heart conditions that weaken or damage the heart muscle. As the disease progresses, individuals may experience symptoms such as fatigue, shortness of breath, and fluid retention. The heart’s ability to pump blood diminishes over time, leading to a reduced capacity for physical activity. This condition can affect either the left, right, or both sides of the heart. It often requires lifestyle adjustments to manage symptoms and improve quality of life.

Heart Failure with Preserved Ejection Fraction – Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart’s pumping ability is normal, but the heart muscle is stiff and does not relax properly. This stiffness leads to increased pressure in the heart and lungs, causing symptoms like shortness of breath and fatigue. Over time, the heart’s ability to fill with blood during the resting phase is impaired, leading to congestion and fluid buildup. HFpEF is often associated with conditions such as hypertension and diabetes. The disease progresses as the heart’s filling capacity continues to decline. It requires careful management to alleviate symptoms and maintain heart function.